Darragh Murnane

List of Publications by Year
in descending order

38 papers	520 citations	777949 13 h-index	759306 22 g-index
40 all docs	40 docs citations	40 times ranked	694 citing authors

#	Article	IF	Citations
1	Development of a New Dislodgeable Foliar Residue Analytical Laboratory Method for Pesticides. Annals of Work Exposures and Health, 2022, 66, 1070-1080.	0.6	1
2	The Influence of Oily Vehicle Composition and Vehicle-Membrane Interactions on the Diffusion of Model Permeants across Barrier Membranes. Membranes, 2021, 11, 57.	1.4	4
3	Crystallographic tomography and molecular modelling of structured organic polycrystalline powders. CrystEngComm, 2021, 23, 2520-2531.	1.3	8
4	Water Uptake by Evaporating pMDI Aerosol Prior to Inhalation Affects Both Regional and Total Deposition in the Respiratory System. Pharmaceutics, 2021, 13, 941.	2.0	6
5	Solid-phase microextraction for assessment of plasma protein binding, a complement to rapid equilibrium dialysis. Bioanalysis, 2021, 13, 1101-1111.	0.6	2
6	High Content Image Analysis as a Tool to Morphologically Distinguish Macrophage Activation and Determine Its Importance for Foamy Alveolar Macrophage Responses. Frontiers in Immunology, 2021, 12, 611280.	2.2	2
7	Wurster Fluidised Bed Coating of Microparticles: Towards Scalable Production of Oral Sustained-Release Liquid Medicines for Patients with Swallowing Difficulties. AAPS PharmSciTech, 2020, 21, 3.	1.5	17
8	Multivariate Analytical Approaches to Identify Key Molecular Properties of Vehicles, Permeants and Membranes That Affect Permeation through Membranes. Pharmaceutics, 2020, 12, 958.	2.0	2
9	Investigating the Suitability of High Content Image Analysis as a Tool to Assess the Reversibility of Foamy Alveolar Macrophage Phenotypes In Vitro. Pharmaceutics, 2020, 12, 262.	2.0	4
10	A digital workflow from crystallographic structure to single crystal particle attributes for predicting the formulation properties of terbutaline sulfate. CrystEngComm, 2020, 22, 3347-3360.	1.3	6
11	Comparison of Oral, Intranasal and Aerosol Administration of Amiodarone in Rats as a Model of Pulmonary Phospholipidosis. Pharmaceutics, 2019, 11, 345.	2.0	11
12	Air Flow Entrainment of Lactose Powder: Simulation and Experiment. IUTAM Symposium on Cellular, Molecular and Tissue Mechanics, 2019, , 107-117.	0.1	2
13	Development of an adaptive bypass element for passive entrainment flow control in dry powder inhalers. Proceedings of the Institution of Mechanical Engineers, Part C: Journal of Mechanical Engineering Science, 2019, 233, 5201-5213.	1.1	3
14	Computational modelling and experimental validation of drug entrainment in a dry powder inhaler. International Journal of Pharmaceutics, 2018, 553, 37-46.	2.6	13
15	Dispersing the Mists: An Experimental History of Medicine Study into the Quality of Volatile Inhalations. Journal of Aerosol Medicine and Pulmonary Drug Delivery, 2017, 30, 157-163.	0.7	0
16	A personalized medicine approach to the design of dry powder inhalers: Selecting the optimal amount of bypass. International Journal of Pharmaceutics, 2017, 529, 589-596.	2.6	9
17	Pulmonary aerosol delivery and the importance of growth dynamics. Therapeutic Delivery, 2017, 8, 1051-1061.	1.2	32
18	Predicting the Fine Particle Fraction of Dry Powder Inhalers Using Artificial Neural Networks. Journal of Pharmaceutical Sciences, 2017, 106, 313-321.	1.6	20

#	Article	IF	Citations
19	Optimizing the Entrainment Geometry of a Dry Powder Inhaler: Methodology and Preliminary Results. Pharmaceutical Research, 2016, 33, 2668-2679.	1.7	17
20	Establishing the importance of oil-membrane interactions on the transmembrane diffusion of physicochemically diverse compounds. International Journal of Pharmaceutics, 2016, 506, 429-437.	2.6	4
21	Interaction of Formulation and Device Factors Determine the In Vitro Performance of Salbutamol Sulphate Dry Powders for Inhalation. Journal of Pharmaceutical Sciences, 2015, 104, 3861-3869.	1.6	7
22	Mathematical approach for understanding deagglomeration behaviour of drug powder in formulations with coarse carrier. Asian Journal of Pharmaceutical Sciences, 2015, 10, 501-512.	4.3	3
23	Direct Ionization of Solid-Phase Microextraction Fibers for Quantitative Drug Bioanalysis: From Peripheral Circulation to Mass Spectrometry Detection. Analytical Chemistry, 2015, 87, 754-759.	3.2	52
24	Formulation Pre-screening of Inhalation Powders Using Computational Atomâ€“Atom Systematic Search Method. Molecular Pharmaceutics, 2015, 12, 18-33.	2.3	43
25	The Challenges of Paediatric Pulmonary Drug Delivery. AAPS Advances in the Pharmaceutical Sciences Series, 2014, , 253-272.	0.2	0
26	Buccal/Sublingual Drug Delivery for the Paediatric Population. AAPS Advances in the Pharmaceutical Sciences Series, 2014, , 205-215.	0.2	0
27	Potential of a Cyclone Prototype Spacer to Improve In Vitro Dry Powder Delivery. Pharmaceutical Research, 2014, 31, 1133-1145.	1.7	11
28	Evidence for the existence of powder sub-populations in micronized materials: Aerodynamic size-fractions of aerosolized powders possess distinct physicochemical properties.. Pharmaceutical Research, 2014, 31, 3251-3264.	1.7	9
29	Dynamics of aerosol size during inhalation: Hygroscopic growth of commercial nebulizer formulations. International Journal of Pharmaceutics, 2014, 463, 50-61.	2.6	41
30	Rapid characterisation of the inherent dispersibility of respirable powders using dry dispersion laser diffraction. International Journal of Pharmaceutics, 2013, 447, 124-131.	2.6	49
31	Nitrogen-14 Nuclear Quadrupole Resonance Spectroscopy: A Promising Analytical Methodology for Medicines Authentication and Counterfeit Antimalarial Analysis. Analytical Chemistry, 2013, 85, 2746-2753.	3.2	34
32	Dry Powder Formulations for Inhalation of Fluticasone Propionate and Salmeterol Xinafoate Microcrystals. Journal of Pharmaceutical Sciences, 2009, 98, 503-515.	1.6	20
33	Investigations into the Formulation of Metered Dose Inhalers of Salmeterol Xinafoate and Fluticasone Propionate Microcrystals. Pharmaceutical Research, 2008, 25, 2283-2291.	1.7	12
34	Polymorphic control of inhalation microparticles prepared by crystallization. International Journal of Pharmaceutics, 2008, 361, 141-149.	2.6	12
35	Comparison of salmeterol xinafoate microparticle production by conventional and novel antisolvent crystallization. European Journal of Pharmaceutics and Biopharmaceutics, 2008, 69, 94-105.	2.0	17
36	Developing an environmentally benign process for the production of microparticles: Amphiphilic crystallization. European Journal of Pharmaceutics and Biopharmaceutics, 2008, 69, 72-82.	2.0	21

#	Article	IF	Citations
37	Crystallization and Crystallinity of Fluticasone Propionate. Crystal Growth and Design, 2008, 8, 2753-2764.	1.4	19
38	In situ and Ex situ Analysis of Salmeterol Xinafoate Microcrystal Formation from Poly(ethylene) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 70	1.4	6